GSK plc (LSE/NYSE: GSK) released encouraging top-line outcomes from MATINEE in adult patients suffering from chronic obstructive pulmonary disease (COPD).
Ventyx Biosciences announced that the initial patient has been administered a dose in a Phase 2a study of VTX3232 for individuals with early-stage Parkinson’s disease.
Sep 10th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Crestone, Inc. ("Crestone") announced promising initial results from its Phase 2 clinical trial of CRS3123 in patients with Clostridioides difficile infection (CDI).